Telperian

What Telperian does

Telperian is a privately held clinical trial intelligence company, founded circa 2018 and headquartered in Dallas, Texas, that sells AI-powered software and biostatistical services to pharmaceutical and biotech sponsors. Its commercial offering is organized into two integrated platforms: Data Design & Intelligence (DDI), covering trial design and simulation through Emulogic® (publication-to-patient-level data emulation), Biostat Autopilot™ (no-code statistical analysis), Machine Learning Capabilities, and the Virtual Trial Simulator; and FDA Deliverables & Tech-Enabled Services (TES), covering submission preparation and oversight through Foundation Explore, Patient Landscapes, and the TFL Generator (automated CDISC SDTM/ADaM-aligned tables, figures, and listings with 21 CFR Part 11 audit trails). The company reports it has supported over 60 trials and contributed to FDA submissions with zero statistical comments, with named work spanning oncology, rare diseases, and acute inflammatory and immunologic conditions, including a publicly disclosed collaboration with CalciMedica (October 2025) on Auxora pivotal-trial design.

The company's revenue model combines subscription or enterprise SaaS access to its DDI/TES platforms with project-based strategic consulting and statistical analysis services, priced on a quote-based enterprise model with no public disclosure. Go-to-market is direct enterprise sales targeting clinical development leads, biostatistics teams, and regulatory strategy professionals at pharma and biotech companies, supported by content marketing (blog, LinkedIn, Twitter/X, PRNewswire). Customer concentration evidence is thin: CalciMedica is the only publicly named customer despite the 60-trial claim.

The leadership bench is unusually credentialed for a 1–10 employee firm, including co-founder and CEO Rick Landin (Ph.D. statistics, Texas A&M; 25+ years drug development across Eli Lilly, Biogen, Neurocrine, and others), co-founder and CSCIO Brian Hobbs (Ph.D. biostatistics, University of Minnesota; tenured Associate Professor at UT Dell Medical School), co-founder Mike Kane (Assistant Professor of Biostatistics at Yale; John M. Chambers Statistical Software award recipient), co-founder Adam Sharp (CEO of CRO SimulStat), co-founder David Hong (Full Professor and Deputy Chair, MD Anderson), President/COAO R. Stephen Eckert (ex-Pfizer, Genzyme, Exact Sciences), CTO Ryan Hafen (Ph.D. Purdue), and CFO Braden Manifold (ex-WellSky, GenesisCare, eviCore).

Name

Telperian

Legal name

Telperian

Website

https://telperian.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Telperian is a Dallas-based clinical trial intelligence company that sells AI-powered biostatistics, trial simulation, and CDISC-compliant FDA submission software to pharmaceutical and biotech sponsors, with stated support for over 60 trials and zero statistical comments on FDA-facing submissions.

Ownership category

akta.pro rank

Product category

Clinical Trial Intelligence Software

NAICS

Other Scientific and Technical Consulting Services (541690)

SIC

Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)

Keywords

• Clinical trial analytics
• Biostatistics software
• Clinical trial design
• Regulatory submission tools
• Pharmaceutical intelligence

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Intelligence Solutions: B2B SaaS and consulting services model providing AI-powered trial design, analysis, and regulatory submission tools to pharmaceutical and biotech companies. Revenue appears to come from software platform subscriptions combined with professional services for implementation and regulatory support.
2. Strategic Consulting & Analysis Services: Deep analytical services including clinical trial data analysis, regulatory discussion support, and pivotal program planning. The CalciMedica collaboration demonstrates project-based consulting engagements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Telperian sells AI-powered clinical trial intelligence software and related services to pharmaceutical and biotechnology companies. Its platform helps sponsors emulate patient-level data from publications, simulate trial designs, automate biostatistical analysis, and generate FDA-compliant tables, figures, and listings for regulatory submissions across therapeutic areas including oncology, rare diseases, and inflammatory conditions.

Product overview

Telperian is a clinical trial intelligence company offering a dual-platform architecture: Data Design & Intelligence (DDI) and FDA Deliverables & Tech-Enabled Services (TES). DDI comprises Emulogic® (patient-level data emulation from publications), Biostat Autopilot™ (no-code statistical analysis engine), Machine Learning Capabilities (subpopulation analysis), and Virtual Trial Simulator (trial design scenario modeling). TES includes Foundation Explore (real-time patient-level dashboards), Patient Landscapes (population profiling), and TFL Generator (automated CDISC-compliant tables, figures, and listings). The platforms are designed to work together, with AI powering analysis across the entire trial lifecycle from protocol design through regulatory submission.

Differentiator

Problem solved

Functional benefit

Products and services

• Emulogic® Proprietary simulation engine that emulates patient-level source data from published scientific results, enabling clinical trial sponsors to stress-test trial assumptions, optimize statistical power, and reduce the risk of costly protocol amendments before finalizing protocols.
• Biostat Autopilot™ No-code statistical engine that automates biostatistical analysis at scale, transforming raw or emulated clinical datasets into validated insights and submission-ready outputs including core TLFs, covariate-stratified summaries, and multi-site/subgroup analyses for biostatistics teams.
• Machine Learning Capabilities AI-powered tools that transform clinical datasets into predictive models for subpopulation enrichment, outcome simulation, dropout prediction, and protocol optimization, with explainable, regulator-ready outputs.
• Virtual Trial Simulator Platform for modeling entire clinical study designs using emulated or existing data to test how changes to sample size, stratification, endpoints, and dropout rates affect trial power and performance without coding.
• Foundation Explore Dynamic review interface that transforms raw clinical datasets into interactive patient-level visuals for DMC meetings, ongoing safety assessments, and regulatory communication, with subject-specific dashboards and protocol deviation tracking.
• Patient Landscapes Dynamic population profiling module enabling rapid visualization of demographic, clinical, and biomarker distributions across enrolled or emulated cohorts for stratification balance and eligibility threshold analysis.
• TFL Generator Automated tool for generating FDA-compliant tables, figures, and listings aligned with CDISC SDTM/ADaM standards and 21 CFR Part 11 audit trails, with no-code configuration and drag-and-drop dataset selection for regulatory submissions.
• Data Design & Intelligence (DDI) Platform Integrated workflow platform combining analytics, simulation, and machine learning for clinical trial design, supporting hypothesis generation through protocol simulations for pharmaceutical and biotech sponsors.
• FDA Deliverables & Tech-Enabled Services (TES) Specialized offering for FDA submission preparation, trial oversight, and real-time data review combining automation, compliance, and biostatistical insight across Foundation Explore, Patient Landscapes, and TFL Generator.

Quantifiable outcome

• Saves 6-12 months vs Real World Data solutions
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

One partnership is on record.

• CalciMedicacoreStrategic or Co-development Partner · 14 October 2025Telperian and CalciMedica announced a strategic collaboration on October 14, 2025, to integrate Telperian's AI engine into the analysis of clinical trial datasets from completed trials of Auxora (CalciMedica's lead clinical compound). The partnership aims to optimize trial analysis and support regulatory discussions for Auxora's development in acute inflammatory and immunologic illnesses. Telperian will analyze Phase 2 datasets (CARPO and CARDEA trials) to refine target patient populations and efficacy endpoints for upcoming pivotal trials, and conduct emulations of historical studies in critical care to determine insights for pivotal program planning. Findings will support CalciMedica's discussions with the FDA.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cytel: Specialized biostatistics and clinical trial design firm offering similar statistical services, Bayesian/adaptive trial expertise, and software (e.g., EAST, Solara) to pharma/biotech — directly overlapping with Telperian's core biostatistics and trial simulation positioning.
• Berry Consultants: Statistical consulting firm specializing in Bayesian adaptive clinical trial design, working with pharma/biotech sponsors on trial simulation and design; competes for the same statistical design dollars Telperian targets.
• Phesi: AI/data-driven clinical trial design and feasibility analytics provider; closest concept-level peer using data and AI to inform protocol design and patient population choices, matching Telperian's Emulogic®-style approach.

Broad incumbents

• Medidata (Dassault Systèmes): Industry-leading EDC and clinical trial platform serving large sponsors across design, data capture, and analysis; competes with Telperian at the FDA-submission workflow layer but as a broad incumbent rather than niche design/simulation specialist.
• IQVIA: Largest global CRO and life sciences data/AI provider, including biostatistics and design services; competes for the same enterprise pharma R&D budget as Telperian but at much greater scale and as a full-service CRO relationship.
• Clario: Clinical trial technology company providing EDC, imaging, eCOA, and patient-centric trial solutions; another broad incumbent competing for sponsor technology spend that also touches Telperian's data and TFL workflow.
• Veeva Systems: Major life sciences cloud platform with clinical operations, EDC (Vault CDB), and trial management suites used by most large pharmas; overlaps with Telperian's FDA Deliverables & Tech-Enabled Services on workflow and submission outputs.

Emerging players

• Unlearn.AI: Uses AI to generate digital twins and accelerate clinical trial design/enrollment for sponsors; operates in the same AI-generated synthetic patient data and trial design optimization niche as Telperian's Emulogic® emulation capability.
• Saama Technologies: AI/analytics company focused on clinical development, including patient stratification, trial design analytics, and submission automation; an emerging specialist with overlapping AI-for-trial-design ambitions to Telperian's suite.
• Inato: AI-driven clinical trial site selection and feasibility platform for biotech sponsors; overlaps in the AI-enabled trial design and patient/feasibility analytics space that Telperian's Patient Landscapes and Emulogic® address.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TelperianInc
• LinkedInlinkedin.com/company/telperian

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Telperian